Page 6,484«..1020..6,4836,4846,4856,486..6,4906,500..»

RNL BIO, a South Korean adult stem cell firm, introduces its autologous stem cell therapeutics in Turkey to treat …

Posted: Published on September 13th, 2012

SEOUL, South Korea, Sept. 13, 2012 /PRNewswire/ --RNL Bio (www.rnl.co.kr) announced on Sep 11, 2012 that it signed the agreement with RST Biomedikal Sanayi A.S. (RST), a Turkish company, to license RNL Bio's stem cell technology. Turkey is the 6th country where RNL Bio's stem cell technology has entered. This is one of the major accomplishments that RNL BIO has long focused on establishing the so-called 'Stem Cell Silk Road' with South Korean stem cell technology to give hope to patients with intractable diseases in the world. RST as a licensee will pay the $5 million fee upfront within 60 days from the agreement and will continue to pay the running royalty of 15% of the revenue, which could be up to $ 200 million. RST will benefit from the geographical advantages of Turkey where Western, Arabic and Oriental cultures are crossed. It plans to establish a GMP facility and invite patients from Europe and Middle East early next year. Ilknur Erdemin, CEO of RST said, "We expect to improve public health and the quality of life in Turkey through stem cell therapy technology imported from RNL BIO in treating various intractable diseases. We will also grow Turkey to one … Continue reading

Comments Off on RNL BIO, a South Korean adult stem cell firm, introduces its autologous stem cell therapeutics in Turkey to treat …

Help with Social Skills – High Functioning Autism – Themes Games and Activites – Video

Posted: Published on September 13th, 2012

12-09-2012 14:03 This game is designed to help your child on the Autism Spectrum broaden and expand their conversation skills. Often our children are only interested in talking about themselves or their favorite topic of conversation. This game helps a child to find out and discover things about another person. More here: Help with Social Skills - High Functioning Autism - Themes Games and Activites - Video … Continue reading

Comments Off on Help with Social Skills – High Functioning Autism – Themes Games and Activites – Video

Genetic test for autism developed

Posted: Published on September 13th, 2012

AUSTRALIAN researchers have developed the first known genetic test to predict the risk of children developing an autism spectrum disorder (ASD). Further studies are needed before the blood test becomes available, which could take another five years, but researchers say early results indicate the test can predict the likelihood of developing an ASD with a 72 per cent success rate. The team of researchers led by the University of Melbourne made another significant finding, published in the journal Molecular Psychiatry this week, that could potentially lead to drug treatments for ASD. The scientists identified genes that protect against ASD, in addition to genes linked to an increased risk of the disorders. Both would be used in the genetic test to produce a higher or lower risk of developing autism, a condition characterised by abnormal social interaction, impaired communication and repetitive behaviours. Lead researcher Professor Stan Skafidas from the University of Melbourne said it may be possible in future to harness those protective genes to develop new pharmacological treatments. The genetic test could help clinicians provide treatment earlier to children and reduce the lengthy time it currently takes to diagnose the disorders. However, Prof Skafidas conceded that the 72 per cent … Continue reading

Comments Off on Genetic test for autism developed

Genetic test to predict autism in children

Posted: Published on September 13th, 2012

The Irish Times - Thursday, September 13, 2012 PAUL CULLEN, Health Correspondent AUSTRALIAN SCIENTISTS have developed a genetic test to predict autism spectrum disorder in children, which could provide a long-sought way for early detection and intervention. The test correctly predicted autism with more than 70 per cent accuracy in people of central European descent, with research into other ethnic groups continuing, according to a study published yesterday. However, a leading Irish autism expert urged caution, saying the test was not sufficiently accurate to be relied upon by parents seeking a diagnosis for their children. Prof Michael Fitzgerald, professor of child psychiatry at Trinity College Dublin, described the test as a welcome first step but said the success rate was very crude and could not be used in a clinical setting. Its a step in the right direction but far from acceptable. I couldnt imagine telling a parent their child had or didnt have autism on the basis of this, he said. The difficulty of making a diagnosis for small children is even greater than for adults because they are developing rapidly, he pointed out. About one in 150 children has autism, with symptoms ranging from social awkwardness and narrow … Continue reading

Comments Off on Genetic test to predict autism in children

Brain Games Help Parkinson’s Patients

Posted: Published on September 13th, 2012

PARKINSONS & MEMORY: In addition to the motor symptoms in Parkinson's disease, there are also cognitive symptoms which may be evident even in the early stages of the disease. These may include deficits in executive function (especially planning and attention), set-shifting (ability to alternate between two or more tasks), and memory. Approximately 25%-30% of Parkinson's patients develop dementia. It is not yet known whether dementia is actually a symptom of Parkinson's disease or whether patients with Parkinson's disease are for some reason also at higher risk for dementia. A large number of Parkinson's patients also experience psychiatric disorders such as depression, anxiety, or sleep disorders. Because Parkinson's disease damages neurons in the substantia nigra which produce dopamine, treatment usually involves drugs which work to counteract this shortage of dopamine. Parkinson's patients may benefit from treatment with several kinds of drugs simultaneously. These drugs can often combat the motor symptoms for a long time, but as the disease progresses and the substantia nigra continues to degrade, the drugs eventually become less effective. Some patients whose motor symptoms cannot be controlled by medication undergo brain surgery to destroy portions of the brain regions responsible for some of the motor symptoms in Parkinson's … Continue reading

Posted in Parkinson's Treatment | Comments Off on Brain Games Help Parkinson’s Patients

Sifton teen guilty of setting his home on fire

Posted: Published on September 13th, 2012

Bob Albrecht Columbian files A fire started by a Sifton teen, Alex Michael Smith, destroyed this house the morning of May 13, 2011. Smith was found guilty Wednesday of first-degree arson. By Laura McVicker Columbian Staff Reporter Wednesday, September 12, 2012 Alex Michael Smith suffered a traumatic brain injury eight days before he allegedly burned his family's house down in May 2011. The question before a Clark County judge on Wednesday: Did the Sifton teenager's brain injury prevent him from forming the legal intent to commit first-degree arson? Clark County Superior Court Judge Robert Lewis said the evidence was clear: Smith acted "knowingly and maliciously." "He intended to do it," the judge said. "He was aware his actions were going to cause the fire." After hearing testimony in the daylong trial, Lewis found Smith, now 17, guilty of first-degree arson. The teen will be sentenced on Oct. 2. In juvenile court, judges, not juries, decide a defendant's fate. Read more: Sifton teen guilty of setting his home on fire … Continue reading

Posted in Brain Injury Treatment | Comments Off on Sifton teen guilty of setting his home on fire

Pate Rehabilitation Celebrates Grand Opening of Fort Worth Facility

Posted: Published on September 13th, 2012

DALLAS--(BUSINESS WIRE)-- Pate Rehabilitation, delivering evidence-based treatment and support programs for individuals recovering from acquired brain injuries (ABIs), today announced the grand opening of Savanna Oaks Ranch, its latest residential facility located in Fort Worth, Texas. The ribbon cutting event will take place on Thursday, Sept. 20 from 11 a.m. to 3 p.m. at 232 Bens Trail, Fort Worth, Texas 76120. It will feature informative speeches, a health fair and giveaways for visitors from the local community. To emphasize that every 16 seconds a person suffers a traumatic brain injury (TBI) in the United States, TryMunity.com, a social networking site for traumatic brain injury survivors, will give away a BMX bicycle and helmet every 16 minutes from 1:00 to 3:00 during the event. The drawing is open to all attendees and winners must be available to take the prize home that day. For attending rehabilitation professionals, Pate is providing a Continuing Education Unit (CEU) course at 12:15 p.m., which includes an overview of brain anatomy, types of brain injury, complications and treatment titled The Brain, Brain Injury and Recovery. The course will be free to the first 50 who pre-register. To enroll visit http://www.pate.splashthat.com or call 800-992-1149. Savanna Oaks Ranch … Continue reading

Posted in Brain Injury Treatment | Comments Off on Pate Rehabilitation Celebrates Grand Opening of Fort Worth Facility

FDA OKs Sanofis' MS Drug Aubagio

Posted: Published on September 13th, 2012

(RTTNews.com) - The U.S. Food and Drug Administration Wednesday approved Sanofi's (SNY) multiple sclerosis drug Aubagio as a once daily tablet for the treatment of adults with relapsing forms of the disease. In a clinical trial, the relapse rate for patients using Aubagio was about 30 percent lower than the rate for those taking a placebo. The drug contains a Boxed Warning to the risk of liver problems, including death, and a risk of birth defects. Physicians should do blood tests to check liver function before a patient starts taking Aubagio and periodically during treatment. Also included in the Boxed Warning is an alert noting that the drug may cause fetal harm. The most common side effects of Aubagio experienced by patients in clinical trials include diarrhea, abnormal liver tests, nausea, and hair loss. Multiple Sclerosis, or MS, is a chronic, inflammatory, autoimmune disease of the central nervous system that disrupts communication between the brain and other parts of the body. It is among the most common causes of neurological disability in young adults and occurs at least twice as frequently in women as in men. For most people with MS, episodes of worsening function (relapses) are initially followed by … Continue reading

Posted in MS Treatment | Comments Off on FDA OKs Sanofis' MS Drug Aubagio

FDA Approves Sanofi MS Drug Aubagio

Posted: Published on September 13th, 2012

By Jennifer Corbett Dooren WASHINGTON--The U.S. Food and Drug Administration Wednesday approved a Sanofi SA (SNY, SAN.FR) pill to treat multiple sclerosis, making it the second oral therapy that will be available on the U.S. market. The drug, teriflunomide, will be sold with the brand name Aubagio to treat people with the relapsing remitting form of MS. Multiple sclerosis is a progressive disease that involves damage to nerves controlling muscles and vision; it affects about 400,000 Americans and 2.5 million people world-wide. The condition causes the body's immune system to eat away at the protective covering of the nerves, or myelin, which disrupts the electrical signals between the brain and the rest of the body. Most MS patients are of the "relapsing- remitting" type, where the disease flares up periodically and largely disappears for long periods of time. Aubagio will compete with Novartis AG's (NVS) oral pill Gilenya, which was approved by the FDA in 2010 and has been available in Europe since 2011. FDA said a clinical trial showed the relapse rate for patients using Aubagio was about 30% lower than the rate for those taking a placebo, or sugar pill. The product was approved with FDA's strictest boxed … Continue reading

Posted in MS Treatment | Comments Off on FDA Approves Sanofi MS Drug Aubagio

FDA approves new multiple sclerosis treatment Aubagio

Posted: Published on September 13th, 2012

FDA NEWS RELEASE For Immediate Release: Sept. 12, 2012 Media Inquiries: Sandy Walsh, 301-796-4669, sandy.walsh@fda.hhs.gov Consumer Inquiries: 888-INFO-FDA FDA approves new multiple sclerosis treatment Aubagio The U.S. Food and Drug Administration today approved Aubagio (teriflunomide), a once-a-day tablet for the treatment of adults with relapsing forms of multiple sclerosis (MS). In a clinical trial, the relapse rate for patients using Aubagio was about 30 percent lower than the rate for those taking a placebo, said Russell Katz, M.D., director of the Division of Neurology Products in the FDAs Center for Drug Evaluation and Research. Multiple sclerosis can impair movement, sensation, and thinking, so it is important to have a variety of treatment options available to patients. MS is a chronic, inflammatory, autoimmune disease of the central nervous system that disrupts communication between the brain and other parts of the body. It is among the most common causes of neurological disability in young adults and occurs at least twice as frequently in women as in men. For most people with MS, episodes of worsening function (relapses) are initially followed by recovery periods (remissions). Over time, recovery periods may be incomplete, leading to progressive decline. The most common side effects of Aubagio … Continue reading

Posted in MS Treatment | Comments Off on FDA approves new multiple sclerosis treatment Aubagio

Page 6,484«..1020..6,4836,4846,4856,486..6,4906,500..»